SurModics Inc. (NASDAQ:SRDX) was downgraded by analysts at TheStreet from a “buy” rating to a “hold” rating in a report issued on Monday.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research raised shares of SurModics from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Thursday, October 20th. Sidoti cut shares of SurModics from a “buy” rating to a “neutral” rating and set a $33.00 target price on the stock. in a report on Thursday, October 6th. Finally, Barrington Research cut shares of SurModics from an “outperform” rating to a “market perform” rating in a report on Monday, November 21st.

Shares of SurModics (NASDAQ:SRDX) traded down 2.41% on Monday, hitting $24.30. The stock had a trading volume of 92,901 shares. The firm has a 50-day moving average of $26.64 and a 200 day moving average of $26.23. SurModics has a 1-year low of $17.45 and a 1-year high of $30.75. The company has a market capitalization of $318.04 million, a PE ratio of 31.97 and a beta of 0.98.

SurModics (NASDAQ:SRDX) last posted its quarterly earnings results on Wednesday, November 16th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.17. The company had revenue of $18.20 million for the quarter, compared to analysts’ expectations of $16.09 million. SurModics had a net margin of 13.99% and a return on equity of 15.98%. SurModics’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 EPS. On average, equities analysts anticipate that SurModics will post $1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Financial Market News and is the propert of of Financial Market News. If you are viewing this article on another site, it was copied illegally and reposted in violation of international trademark & copyright law. The correct version of this article can be viewed at http://www.financial-market-news.com/surmodics-inc-srdx-stock-rating-lowered-by-thestreet/1209482/.

In other SurModics news, CEO Gary R. Maharaj sold 5,000 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $29.55, for a total transaction of $147,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.20% of the company’s stock.

A number of large investors have recently modified their holdings of SRDX. Capstone Asset Management Co. raised its position in SurModics by 1.6% in the third quarter. Capstone Asset Management Co. now owns 8,780 shares of the company’s stock worth $264,000 after buying an additional 140 shares during the period. California State Teachers Retirement System raised its position in SurModics by 1.1% in the third quarter. California State Teachers Retirement System now owns 27,414 shares of the company’s stock worth $825,000 after buying an additional 300 shares during the period. First Quadrant L P CA raised its position in SurModics by 9.4% in the third quarter. First Quadrant L P CA now owns 4,374 shares of the company’s stock worth $132,000 after buying an additional 374 shares during the period. Prudential Financial Inc. raised its position in SurModics by 1.0% in the second quarter. Prudential Financial Inc. now owns 46,622 shares of the company’s stock worth $1,095,000 after buying an additional 460 shares during the period. Finally, Two Sigma Advisers LP raised its position in SurModics by 2.2% in the third quarter. Two Sigma Advisers LP now owns 41,073 shares of the company’s stock worth $1,236,000 after buying an additional 900 shares during the period. 88.55% of the stock is currently owned by institutional investors and hedge funds.

SurModics Company Profile

SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.

5 Day Chart for NASDAQ:SRDX

Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.